美国批准PD-L1单抗Tecentriq,用于非小细胞肺癌的一线治疗

2020-05-19 MedSci原创 MedSci原创

在美国,PD-L1单抗Tecentriq(atezolizumab)已获得NSCLC的四项批准。

美国食品和药物管理局已批准罗氏的PD-L1单抗Tecentriq(atezolizumab)用于治疗PD-L1高表达,且无EGFR或ALK基因突变的转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。

该决定是基于III期研究IMpower110的中期分析数据,该研究表明在PD-L1高表达患者中,与化学疗法相比,Tecentriq单药治疗可提高7.1个月的总生存期(OS),中位OS分别为13.1个月和20.2个月。

此外,Tecentriq的安全性与其已知的安全性相一致,没有引发新的问题。接受Tecentriq治疗的患者中有3-4级与治疗相关的不良事件(AE)的占比12.9%,而接受化疗的为44.1%。

Tecentriq是首个也是唯一一种可以三种剂量给药的单药癌症免疫疗法,允许每两周、三周或四周一次给药。

在美国,该药物已获得NSCLC的四项批准,包括作为单一药物或与靶向疗法和化学疗法联合使用,也被批准与卡铂和依托泊苷(化学疗法)联合用于成人广泛期小细胞肺癌的一线治疗。

原始出处:

http://www.pharmatimes.com/news/new_us_nod_for_roches_tecentriq_in_nsclc_1340517

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
    2021-02-25 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
    2020-05-21 smartjoy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
    2020-05-21 lfyang
  7. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1652419, encodeId=b47616524193b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Feb 25 05:51:02 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059901, encodeId=785d2059901df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jan 31 23:51:02 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055050, encodeId=73082055050d3, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu Oct 08 10:51:02 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388117, encodeId=9eb0138811e2c, content=<a href='/topic/show?id=9fb013926c5' target=_blank style='color:#2F92EE;'>#PD-L1单抗Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13926, encryptionId=9fb013926c5, topicName=PD-L1单抗Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL9IcRyHXOosY80XM2dxHicLicaXu4SDK8ok08RUHt8shK0P1kzfmDicn5gowfFgkn602PZia0MMmgcgA/132, createdBy=73052500015, createdName=ms117281293605716, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Thu May 21 09:51:02 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382986, encodeId=2959382986cc, content=好文章,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Wed May 20 06:37:25 CST 2020, time=2020-05-20, status=1, ipAttribution=)]
    2020-05-20 njwbhuang

    好文章,感谢分享

    0

相关资讯

AACR 2020:肿瘤浸润淋巴细胞(TIL)疗法挑战PD-1耐药性肺癌

TIL疗法治疗PD-1耐药性非小细胞肺癌患者的1期结果积极。其实在去年的ASCO年会上,Iovance Biotherapeutics公司就公布了其创新细胞疗法LN-145和lifleucel在治疗宫

FDA批准了针对RET基因突变或融合癌症的药物--Retevmo

FDA批准Retevmo用于治疗三种RET基因发生突变或融合的肿瘤--非小细胞肺癌,甲状腺髓样癌和其他甲状腺癌。

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合,一线治疗非小细胞肺癌

百事美施贵宝(Bristol Myers Squibb)公司宣布,FDA已批准其PD-1单抗Opdivo(nivolumab)和CTLA-4单抗Yervoy(ipilimumab)联合,用于治疗PD-

ASCO 2020:罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合,延长了非小细胞肺癌患者生存期

TIGIT靶向抗体tiragolumab与Tecentriq组合能够提高NSCLC患者的客观缓解率和无进展生存期。

Lancet Oncol :Atezolizumab联合卡波铂和nab-paclitaxel用于非小细胞肺癌术前化疗

Atezolizumab联合卡波铂和nab-paclitaxel治疗可作为可切除非小细胞肺癌术前化疗的新辅助治疗方案,有很高比例的患者获得了病理反应

NAT MED:我国公布CRISPR人体试验结果

在此,我国研究人员报告了CRISPR-Cas9 PD-1编辑的T细胞在晚期非小细胞肺癌患者中的首例人体I期临床试验的结果(ClinicalTrials.gov NCT02793856)。